Latest Advances in Lung Cancer Research

Large trial finds nivolumab after lung cancer surgery didn’t improve survival or prevent recurrence compared to observation alone.

Selpercatinib cut lung cancer recurrence risk by 83% in patients with rare RET-positive early-stage non-small cell lung cancer.

A new lung cancer drug is making headlines. At the 2026 ASCO meeting, researchers shared exciting results for a drug called ivonescimab. In a large study, it lowered the risk of death by 34% for people with a hard-to-treat type of lung cancer.

New drug ivonescimab cut death risk 34% in lung cancer trial, outperforming standard immunotherapy plus chemo combination.

A new UK study found lung cancer survivors living in high-pollution areas had over 6 times the risk of a second, separate lung cancer.

For many years, small cell lung cancer treatments stayed mostly the same. Chemotherapy was the main option, and immunotherapy added in 2018 only helped a little. But now, new therapies are bringing real hope to patients and their families.

New data shows elisrasib provides strong, lasting tumor responses for advanced lung cancer patients, including those who failed previous KRAS-targeted treatments.

Drs. Riely and Levy explain the necessity of reflex genomic testing in lung cancer to ensure personalized treatment and better patient outcomes.

Researchers from Yale University looked at more than 28,000 older adults with early-stage non-small cell lung cancer. They found that Black patients were 8 to 9 percentage points less likely than White patients to receive curative treatment.

New pill sevabertinib (Hyrnuo) shrinks tumors in 70% of patients with rare HER2-mutated lung cancer. Learn about this FDA fast-tracked breakthrough.